In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.

zacks.com - 2026-07-14 18:51:13

Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.

fool.com - 2026-07-11 16:30:00

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.

zacks.com - 2026-07-08 18:51:07

Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.

zacks.com - 2026-07-08 09:35:14

Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.

fool.com - 2026-07-05 06:03:00

Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerate drug discovery across several therapeutic areas.

fool.com - 2026-07-04 09:21:09

Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets to accelerate drug discovery via high-tech collaborations.

fool.com - 2026-07-03 11:14:15

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

247wallst.com - 2026-06-30 09:38:29

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

fool.com - 2026-06-30 07:45:03

Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds.

fool.com - 2026-06-26 00:15:00

Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.

zacks.com - 2026-06-24 18:50:17

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.

zacks.com - 2026-06-16 18:51:16

Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors, with Q1'26 earnings noting no dose-limiting toxicities so far. Initial DHALIA trial data are based on a small cohort of 16 patients, with the drug only now reaching relevant dose levels for anti-tumor activity, limiting conclusions. A H2 '26 update from DHALIA could confirm anti-tumor activity of REC-1245, but might not have enough additional data to go beyond that.

seekingalpha.com - 2026-06-12 12:43:10

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.

zacks.com - 2026-06-10 18:50:21

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 14:42:24

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-05 12:35:42

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

fool.com - 2026-06-02 17:12:15

Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com .  About Recursion Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives.

globenewswire.com - 2026-06-02 08:00:00

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).

globenewswire.com - 2026-05-29 16:30:00

Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.

globenewswire.com - 2026-05-19 12:07:00

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 17:30:48

The old healthcare model is breaking down.

fool.com - 2026-05-08 07:30:00

Earlier this year, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated discussions with the FDA for the design of a registrational study for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), which represents a new way of treating this rare genetic condition without immediate surgery.

benzinga.com - 2026-05-07 13:04:59

Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.

zacks.com - 2026-05-07 12:30:42

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 19:51:15

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.5 per share a year ago.

zacks.com - 2026-05-06 08:45:40

SALT LAKE CITY, May 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.

globenewswire.com - 2026-05-06 06:30:00

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.41, indicating a -1.45% shift from the previous trading day.

zacks.com - 2026-05-01 18:45:22

Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June 2026 and does not intend to seek re-election to the Company's Board of Directors.

globenewswire.com - 2026-04-30 16:30:00

Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST

globenewswire.com - 2026-04-29 07:59:00

Recursion Pharmaceuticals, Inc. remains a Hold as competitive risks persist and the company is years away from meaningful pipeline revenue. RXRX's AI-driven Recursion OS platform shows strong potential, but has yet to demonstrate a clear competitive edge or superior scalability versus well-funded peers. Share dilution and accelerating cash burn threaten RXRX shareholder value, with at least 18-24 months before potential pipeline revenue and likely further capital raises.

seekingalpha.com - 2026-04-27 20:16:55

Recursion Pharmaceuticals (RXRX) reached $3.5 at the closing of the latest trading day, reflecting a -6.17% change compared to its last close.

zacks.com - 2026-04-23 18:51:24

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

seekingalpha.com - 2026-04-17 01:41:47

Recursion Pharmaceuticals (RXRX) closed at $3.6 in the latest trading session, marking a -4% move from the prior day.

zacks.com - 2026-04-16 18:51:14